Label: BENZONATATE capsule, liquid filled
-
Contains inactivated NDC Code(s)
NDC Code(s): 67296-0567-1 - Packager: RedPharm Drug Inc.
- This is a repackaged label.
- Source NDC Code(s): 65162-536
- Category: HUMAN PRESCRIPTION DRUG LABEL
Drug Label Information
Updated July 6, 2011
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
DESCRIPTION
Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.
Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP.
Benzonatate Capsules also contain: D and C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium.
-
CLINICAL PHARMACOLOGY
Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.
-
INDICATIONS AND USAGE
Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.
- CONTRAINDICATIONS
-
WARNINGS
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.
-
PRECAUTIONS
Benzonatate is chemically related to anesthetic agents of the para-aminobenzoic acid class (e.g., procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
Information for the Patient
Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. Therefore, the capsules should be swallowed without chewing.
Usage in Pregnancy:
Pregnancy Category C.
Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzonatate is administered to a nursing woman.Carcinogenesis, Mutagenesis, Impairment of Fertility:
Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.Pediatric Use:
Safety and effectiveness in children below the age of 10 has not been established. -
ADVERSE REACTIONS
Potential Adverse Reactions to benzonatate may include:
Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.
CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.
GI: constipation, nausea, GI upset.
Dermatologic: pruritus; skin eruptions.
Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.
Rare instances of deliberate or accidental overdose have resulted in death.
OVERDOSAGE
Overdose may result in death.
The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.
Signs and Symptoms:
If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly. CNS stimulation may cause restlessness and tremors, which may proceed to clonic convulsions followed by profound CNS depression.Treatment:
Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag refluxes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturates given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.Do not use CNS stimulants.
- DOSAGE AND ADMINISTRATION
-
HOW SUPPLIED
Benzonatate Capsules, USP are available as:
Soft gelatin capsules, 100 mg (oval, yellow); bottle of 100
Imprint: A1.
NDC# 65162-536-10
Soft gelatin capsules, 100 mg (oval, yellow); bottle of 500
Imprint: A1.
NDC# 65162-536-50
Soft gelatin capsules, 200 mg (oblong, yellow); bottle of 100
Imprint: A2.
NDC# 65162-537-10
Store at 25°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP.
Manufactured by:
Swiss Caps AGHausenstrasse 35
CH-9533, Kirchberg, Switzerland
Distributed by:
Amneal Pharmaceuticals
Glasgow, KY 42141
Rev. 09-2008
- PRINCIPAL DISPLAY PANEL
-
INGREDIENTS AND APPEARANCE
BENZONATATE
benzonatate capsule, liquid filledProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67296-0567(NDC:65162-536) Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR) BENZONATATE 100 mg Inactive Ingredients Ingredient Name Strength D&C Yellow No. 10 (UNII: 35SW5USQ3G) gelatin (UNII: 2G86QN327L) glycerin (UNII: PDC6A3C0OX) methylparaben sodium (UNII: CR6K9C2NHK) propylparaben sodium (UNII: 625NNB0G9N) Product Characteristics Color yellow Score no score Shape OVAL (Soft Gelatin Capsules) Size 9mm Flavor Imprint Code A1 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:67296-0567-1 15 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040682 01/13/2010 Labeler - RedPharm Drug Inc. (008039641) Establishment Name Address ID/FEI Business Operations Swiss Caps AG 481784895 MANUFACTURE Establishment Name Address ID/FEI Business Operations Amneal Pharmaceuticals 831227801 LABEL, PACK, analysis